{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:06:22Z","timestamp":1763017582418,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jcyt.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T16:52:59Z","timestamp":1445705579000},"page":"1785-1792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Hematopoietic progenitor cell mobilization with \u201cjust-in-time\u201d plerixafor approach is a cost-effective alternative to routine plerixafor use"],"prefix":"10.1016","volume":"17","author":[{"given":"Lauren","family":"Veltri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Shillingburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Leadmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2015.09.002_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcyt.2015.09.002_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcyt.2015.09.002_bib3","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2015.09.002_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib5","first-page":"311","article-title":"Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma","volume":"4","author":"Moskowitz","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2015.09.002_bib6","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2015.09.002_bib7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1200\/JCO.2000.18.6.1360","article-title":"Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy","volume":"18","author":"Siena","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcyt.2015.09.002_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10245332.1999.11746443","volume":"4","author":"Sola","year":"1999","journal-title":"Hematology"},{"key":"10.1016\/j.jcyt.2015.09.002_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2015.09.002_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bmt.1704466","article-title":"Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma","volume":"33","author":"Kuittinen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib13","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2015.09.002_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jcyt.2015.09.002_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd2819","article-title":"Plerixafor","volume":"8","author":"DiPersio","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2015.09.002_bib16","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.09.002_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/bmt.2010.54","article-title":"Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data","volume":"46","author":"Duarte","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib18","first-page":"931071","article-title":"Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood progenitor cell mobilization","volume":"2012","author":"Awan","year":"2012","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.jcyt.2015.09.002_bib19","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","article-title":"Effectiveness and cost analysis of \u201cjust-in-time\u201d salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics","volume":"51","author":"Li","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2015.09.002_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1537-2995.2011.03206.x","article-title":"Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization","volume":"52","author":"Vishnu","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2015.09.002_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","article-title":"Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization","volume":"19","author":"Micallef","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering","volume":"5","author":"Sutherland","year":"1996","journal-title":"J\u00a0Hematother"},{"key":"10.1016\/j.jcyt.2015.09.002_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jca.21206","article-title":"The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells","volume":"27","author":"Gopal","year":"2012","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.jcyt.2015.09.002_bib27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1537-2995.2011.03349.x","article-title":"Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept","volume":"52","author":"Jantunen","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2015.09.002_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","article-title":"Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization","volume":"50","author":"Sanchez-Ortega","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/14653249.2012.681042","article-title":"Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization","volume":"14","author":"Sancho","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2015.09.002_bib30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbmt.2011.10.002","article-title":"Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections","volume":"18","author":"Gambell","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/bmt.2010.236","article-title":"Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention","volume":"46","author":"Sinha","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib32","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2013.04.019","article-title":"Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes","volume":"19","author":"Kanate","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","article-title":"Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma","volume":"22","author":"Paripati","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2015.09.002_bib34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/bmt.2012.60","article-title":"Growth factor plus preemptive (\u201cjust-in-time\u201d) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure","volume":"47","author":"Costa","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib35","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/leu.2011.308","article-title":"Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies","volume":"26","author":"Sinha","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2015.09.002_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2011.10.003","article-title":"Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide","volume":"18","author":"Malard","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2015.09.002_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","article-title":"Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia","volume":"103","author":"Tournilhac","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2015.09.002_bib38","first-page":"33","article-title":"Economic evaluation of plerixafor for stem cell mobilization","volume":"18","author":"Kymes","year":"2012","journal-title":"Am J Manag Care"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324915010580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324915010580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:21:53Z","timestamp":1761430913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324915010580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1465324915010580"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2015.09.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic progenitor cell mobilization with \u201cjust-in-time\u201d plerixafor approach is a cost-effective alternative to routine plerixafor use","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}